Science

Our research and development strategy is designed to create great value for patients

  • Targeting scientifically well validated mechanism

  • Enhancing the target delivery for the desired effects

  • Accelerating research and drug development through efficient operation

Innovation and acceleration

We approach modulating neuronal signaling and biological pathways to save neuronal cells from various neurologic damages and degenerations and support neuroplasticity.

Our lead asset SPV-400 is a novel Tropomyosin receptor kinase B (TrkB) agonist. Our solution is grounded on the potential therapeutic properties of Brain-Derived Neurotrophic Factor (BDNF)/TrkB pathway in preserving cellular mechanisms and neuroplasticity. SPV-400 is a small molecule TrkB agonist that directly activates the TrkB receptor by overcoming BDNF’s limitations on target delivery.

We accelerate the research and development programs to reach patients through efficiency in each step from discovery to commercial launch in global markets.

 

Partnerships and Collaborations

We believe in the power of collaborations in research and drug development. 

By collaborating with experts in academia and industry through strategic partnerships and open collaboration networks, we uncover opportunities around the world to discover promising treatment candidates and accelerate the development of therapeutic solutions for patients.